gene

PSP

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about PSP: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

348Connections

0Hypotheses

1Analyses

50Outgoing

50Incoming

7Experiments

2Debates

No summary available yet.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	PSP
Full Name	Persephin
Chromosome	19q13.33
Protein Family	GDNF family
Function	Persephin mediates its effects through specific receptor interactions:
Pathways	Differentiation
GeneCards	PSP
Human Protein Atlas	PSP
Globose neurofibrillary tangles	Located in subcortical nuclei including the Subthalamic Nucleus (STN), Globus Pallidus (GP), substantia nigra (SN), and brainstem raphe nuclei[^7]
Tufted astrocytes	Astrocytic inclusions specific to PSP, arranged in tufts around the nucleus
Coiled bodies	Oligodendroglial inclusions in the white matter
Thread-like processes	Tau-positive neurites in the neuropil
Associated Diseases	Aging, Als, Alzheimer, Alzheimer's disease, dementia
Interactions	AGING, AKT, ALZHEIMER, ALZHEIMER'S DISEASE, AMYLOID, AND
KG Connections	348 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    PSP["PSP"] -->|"associated"| Alzheimer["Alzheimer"]
    style Alzheimer fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    PSP["PSP"] -->|"associated"| Als["Als"]
    style Als fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    PSP["PSP"] -->|"associated"| Alzheimer_s_disease["Alzheimer's disease"]
    style Alzheimer_s_disease fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    PSP["PSP"] -->|"expressed in"| neurons["neurons"]
    style neurons fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    PSP["PSP"] -->|"associated"| frontotemporal_dementia["frontotemporal dementia"]
    style frontotemporal_dementia fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
    style oxidative_stress_response fill:#1a2a3a,stroke:#81c784,stroke-width:1px,color:#fff
    PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
    style Ms fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    ALZHEIMER["ALZHEIMER"] -->|"associated"| PSP["PSP"]
    style ALZHEIMER fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    DUSP10["DUSP10"] -->|"associated"| PSP["PSP"]
    style DUSP10 fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    MAP1S["MAP1S"] -->|"associated"| PSP["PSP"]
    style MAP1S fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    TAU["TAU"] -->|"activates"| PSP["PSP"]
    style TAU fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    NEURODEGENERATIVE_DISEASES["NEURODEGENERATIVE DISEASES"] -->|"activates"| PSP["PSP"]
    style NEURODEGENERATIVE_DISEASES fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    style PSP fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0,font-weight:bold

Outgoing (214)

Target	Relation	Type	Str
Als	associated_with	disease	0.85
Alzheimer	associated_with	disease	0.85
Alzheimer's disease	associated_with	disease	0.80
neurons	expressed_in	cell_type	0.80
ALZHEIMER'S DISEASE	associated_with	gene	0.80
unfolded protein response	participates_in	pathway	0.75
tauopathy	targets	disease	0.75
SV2A	downregulates	protein	0.75
Parkinson's disease	regulates	disease	0.70
frontotemporal dementia	associated_with	disease	0.70
STX6	regulates	gene	0.70
Parkinson's disease	associated_with	disease	0.70
oxidative stress response	participates_in	pathway	0.70
Als	stabilizes	disease	0.65
Ms	associated_with	disease	0.65
Aging	associated_with	disease	0.65
Neurodegeneration	associated_with	disease	0.65
Senescence	associated_with	disease	0.65
Traumatic Brain Injury	associated_with	disease	0.65
Sarcopenia	therapeutic_target	disease	0.65
astrocytes	expressed_in	cell_type	0.65
Tauopathy	interacts_with	disease	0.65
Alzheimer	interacts_with	disease	0.65
Dementia	interacts_with	disease	0.65
ALS	interacts_with	disease	0.65
Aging	treats	disease	0.65
Neurodegeneration	interacts_with	disease	0.65
Als	activates	disease	0.65
Dementia	associated_with	disease	0.65
Ms	therapeutic_target	disease	0.65
Tauopathy	therapeutic_target	disease	0.65
Alzheimer	stabilizes	disease	0.65
Neurodegeneration	therapeutic_target	disease	0.65
Alzheimer	therapeutic_target	disease	0.65
Amyotrophic Lateral Sclerosis	therapeutic_target	disease	0.65
Dementia	expressed_in	disease	0.65
Parkinson	therapeutic_target	disease	0.65
Als	therapeutic_target	disease	0.65
Als	expressed_in	disease	0.65
Amyotrophic Lateral Sclerosis	expressed_in	disease	0.65
Aging	activates	disease	0.65
ALS	associated_with	disease	0.65
Cancer	inhibits	disease	0.65
Tauopathy	activates	disease	0.65
tauopathy	associated_with	disease	0.65
Ms	biomarker_for	disease	0.65
Neuropathy	inhibits	disease	0.65
Alzheimer	inhibits	disease	0.65
Senescence	therapeutic_target	disease	0.65
ALS	activates	disease	0.65

Incoming (134)

Source	Relation	Type	Str
therapeutics-section-209-glp-1-receptor-agonists-cbs-psp	describes	wiki_page	1.00
MOBP	regulates	gene	0.70
ALZHEIMER	associated_with	gene	0.70
NLGN1	inhibits	gene	0.60
PI3K	associated_with	gene	0.60
PI3K	inhibits	gene	0.60
C6	regulates	gene	0.60
GPR37	associated_with	gene	0.60
NFL	regulates	gene	0.60
C4A	regulates	gene	0.60
C4A	interacts_with	gene	0.60
C4A	causes	gene	0.60
APOE	regulates	gene	0.60
DUSP10	regulates	gene	0.60
EIF2AK3	regulates	gene	0.60
ABCA7	associated_with	gene	0.60
ATP13A2	associated_with	gene	0.60
BSN	associated_with	gene	0.60
CYLD	associated_with	gene	0.60
OPTN	associated_with	gene	0.60
PSEN2	associated_with	gene	0.60
TAU	activates	gene	0.60
NEURODEGENERATIVE DISEASES	activates	gene	0.60
GENES	activates	gene	0.60
ALZHEIMER'S DISEASE	associated_with	gene	0.60
GENETIC MODIFIERS	activates	gene	0.60
TAUOPATHY	activates	gene	0.60
ERK	interacts_with	gene	0.60
TAU	expressed_in	gene	0.60
UBIQUITIN	expressed_in	gene	0.60
P62	expressed_in	gene	0.60
TUBULIN	inhibits	gene	0.60
APOPTOSIS	associated_with	gene	0.60
PI3K	treats	gene	0.60
NEURODEGENERATIVE DISEASES	associated_with	gene	0.60
SYNAPSE	inhibits	gene	0.60
NEURODEGENERATION	associated_with	gene	0.60
AKT	activates	gene	0.60
PI3K	activates	gene	0.60
MAPT	activates	gene	0.60
TAU	interacts_with	gene	0.60
PSMB7	associated_with	gene	0.60
SLC1A2	interacts_with	gene	0.60
MAPT	interacts_with	gene	0.60
MAPT	regulates	gene	0.60
MAPT	expressed_in	gene	0.60
GBA	associated_with	gene	0.60
GBA	regulates	gene	0.60
AUTOPHAGY	therapeutic_target	gene	0.60
NEURODEGENERATION	therapeutic_target	gene	0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

4R-tau strain-specific spreading patterns in PSP vs CBD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.732

Experiments (7)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Brainstem Circuit Modulation for PSP	clinical	ALS	0.400	0.50	human	proposed	$5,460,000
Tau Spreading Network Mapping via Spatial Transcriptomics in PSP	clinical	Neurodegeneration	0.400	0.50	mouse	proposed	$520,000
4R-Tau Targeting Therapies for PSP and CBS	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$6,550,000
Levodopa Response Determinants in PSP — Biomarker-Guided Prediction St	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000
Tau Pathology Initiation Zone Identification	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000
PSP and CBS Biomarker Validation Study	clinical	ALS	0.400	0.50	human	proposed	$7,500,000
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have N	clinical	ALS	0.400	0.50	human	proposed	$7,500,000

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (2)

Multi-agent debates referencing this entity

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

closed · Rounds: 4 · Score: 0.69 · 2026-04-12

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

closed · Rounds: 7 · Score: 0.91 · 2026-04-10

Related Research

Hypotheses and analyses mentioning PSP in their description or question text

No additional research found

PSP

Understanding Entity Pages

Wiki Pages (21)

Progressive Supranuclear Palsy (PSP)

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Clinical Management Guide for CBS/PSP

CBS/PSP Supplements Guide

Device Therapies Comparison for CBS/PSP

CBS/PSP Rehabilitation Master Guide

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

PI-2620 Tau PET in PSP

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

CBS/PSP Treatment Rankings

CBS/PSP Clinical Trials Guide

Lithium for PSP/CBS — Phase 2 Trial

Section 152: Advanced Robotics and Assistive Devices in CBS/PSP

Section 147: Telehealth and Remote Monitoring in CBS/PSP

Section 153: Virtual Reality Therapy Protocols in CBS/PSP

Section 233: Advanced Virtual Reality and Immersive Technology-Based Rehabilitation in CBS/PSP

Metabolomic Alterations in PSP

Variably Protease-Sensitive Prionopathy (VPSPr)

Brain Network Connectivity in PSP

Section 156: Pet Therapy and Animal-Assisted Interventions in CBS/PSP

CBS/PSP Genetic Architecture

Pathway Diagram

Outgoing (214)

Incoming (134)

Targeting Hypotheses (0)

Mentioning Analyses (1)

4R-tau strain-specific spreading patterns in PSP vs CBD

Experiments (7)

Related Papers (0)

Debates (2)

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

Related Research